Anders Pretzmann Mikkelsen

Anders Pretzmann Mikkelsen

Auto-generated profile, based on publicly available information

Anders Pretzmann Mikkelsen

Department of Gynaecology and Obstetrics, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2021 in JAMA
Verified
Journal Article
Open access
PDF file
AMAnders Pretzmann Mikkelsen
Anders Pretzmann Mikkelsen
IGIben Katinka Greiber
Iben Katinka Greiber
NSNikolai Madrid Scheller
Nikolai Madrid Scheller
ØLØjvind Lidegaard
Øjvind Lidegaard
For most women, labor causes severe pain, and methods to alleviate this pain are often required. Epidural analgesia is an effective and commonly used type of neuraxial analgesia used to provide consistent pain relief throughout labor.1,2 In the United States, 73% of women who underwent labor in 2015 were treated with neuraxial analgesia.3 Epidural analgesia during labor is generally considered safe for both mother and child.4,5

26 April 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
ØLØjvind Lidegaard
Øjvind Lidegaard
AMAnders P. Mikkelsen
Anders P. Mikkelsen
PEPia Egerup
Pia Egerup
AKAstrid M. Kolte
Astrid M. Kolte
SRSteen Christian Rasmussen
Steen Christian Rasmussen
HNHenriette S. Nielsen
Henriette S. Nielsen

1 July 2023 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
SLSøren Vinther Larsen
Søren Vinther Larsen
AMAnders Pretzmann Mikkelsen
Anders Pretzmann Mikkelsen
ØLØjvind Lidegaard
Øjvind Lidegaard
VFVibe Gedso Frokjaer
Vibe Gedso Frokjaer
Women are approximately twice as likely to develop depressive episodes compared with men.1 This gap between sexes starts during adolescence, which coincides with menarche in girls, and lasts until menopause.2 Hence, a woman’s reproductive life span is a time of heightened vulnerability for depression, aligning with an increased risk of depression associated with hormonal transitions across the menstrual cycle, when 3% to 8% of women experience premenstrual dysphoric disorder (PMDD)3; the peripartum period, when approximately 13% of women experience postpartum depression (PPD)4; and the perimenopausal period, when large estradiol fluctuations predict risk of perimenopausal depression.5 Concerningly, initiating hormonal contraception (HC) also has been associated with an increased risk of developing a depressive episode.6,7

1 October 2019 in eClinicalMedicine
Verified
Journal Article
Open access
AMAnders P. Mikkelsen
Anders P. Mikkelsen
PEPia Egerup
Pia Egerup
JEJulie F.M. Ebert
Julie F.M. Ebert
AKAstrid M. Kolte
Astrid M. Kolte
HNHenriette S. Nielsen
Henriette S. Nielsen
ØLØjvind Lidegaard
Øjvind Lidegaard
Cancer is the second leading cause of death worldwide. Few studies have investigated if recurrent pregnancy loss is associated with an increased risk of cancer. We aimed to assess whether pregnancy loss is associated with later cancer development. We identified all invasive cancers after age 40, among all Danish women born between January 1957 and December 1972, ensuring a full reproductive history. Cases were matched by birth year 1:10 to cancer-free controls. Women were followed until the end of 2017. The number of pregnancy losses (miscarriages or still births) was correlated to long-term cancer risk using conditional logistic regression, providing odds ratios for specific cancers with different numbers of pregnancy losses, all adjusted for age, education, and other potential confounders. The study included 28,785 women with cancer (mean age 48.7 [SD 5.0]) and 283,294 matched controls (mean age 48.6 [SD 5.0]). We found no overall association between pregnancy loss and later development of 11 site-specific types of cancer or cancer overall. Taking the sequence of pregnancy losses into account, primary recurrent pregnancy loss (three consecutive pregnancy losses without prior live birth) was associated with later overall cancer by an odds ratio of 1.27 (1.04-1.56). Secondary recurrent pregnancy loss showed no association to cancer. Pregnancy loss was not associated with later cancer development. Women with primary recurrent pregnancy loss had a borderline significant association to later cancer overall, this may be a chance finding. Ole Kirk's Foundation and Copenhagen University Hospital Rigshospitalet's Research Grant.

14 December 2020 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
IGIben Katinka Greiber
Iben Katinka Greiber
AMAnders Pretzmann Mikkelsen
Anders Pretzmann Mikkelsen
MKMona Aarenstrup Karlsen
Mona Aarenstrup Karlsen
LSLone Storgaard
Lone Storgaard
JVJakob Viuff
Jakob Viuff
ØLØjvind Lidegaard
Øjvind Lidegaard

29 June 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
AMAnders Pretzmann Mikkelsen
Anders Pretzmann Mikkelsen
IGIben Katinka Greiber
Iben Katinka Greiber
NSNikolai Madrid Scheller
Nikolai Madrid Scheller
MHMalene Hilden
Malene Hilden
ØLØjvind Lidegaard
Øjvind Lidegaard
A recent cohort study comparing females exposed to high cumulative doses versus low cumulative doses of CPA, found a 6–20 fold increased risk of meningioma.3 Subsequently, the European Medicines Agency’s (EMA) issued a recommendation to restrict CPA to less than 10 milligrams per day.4